Drug intelligence / Profile preview

ST80

Development stage: Preclinical
Modality: Small Molecules

Overview

ST80 is a novel hydroxamate derivative that functions as a selective inhibitor of histone deacetylase 6 (HDAC6). It has demonstrated potent growth-inhibitory effects at low micromolar concentrations in various leukemia cell lines (HL60, Kasumi-1, NB-4, THP-1, K562, U937, Jurkat) and primary acute myeloid leukemia (AML) blasts. Its mechanism involves preferentially inducing α-tubulin acetylation, suggesting its antileukemic activity is mediated through HDAC6 inhibition rather than histone reacetylation.

Targets

HDAC1 (Histone Deacetylase 1)HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on ST80.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST80.

Explore the full profile